Go Pro
→ Look at this $5 stock’s address (From Freedom Financial) (Ad)tc pixel Free SRPT Stock Alerts

Sarepta Therapeutics (SRPT) Financials

Sarepta Therapeutics logo
$19.22 -0.51 (-2.58%)
Closing price 04:00 PM Eastern
Extended Trading
$19.26 +0.04 (+0.18%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Sarepta Therapeutics

Annual Income Statements for Sarepta Therapeutics

This table shows Sarepta Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Consolidated Net Income / (Loss)		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Net Income / (Loss) Continuing Operations		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Total Pre-Tax Income 		-220 -267 -49 -363 -714 -553 -419 -690 -520 261 -702
Total Operating Income		 -220 -267 -172 -344 -706 -564 -460 -536 -268 218 -700
Total Gross Profit		 1.25 5.42 155 301 381 540 702 933 1,243 1,902 2,198
Total Revenue		 1.25 5.42 155 301 381 540 702 933 1,243 1,902 2,198
Operating Revenue		 1.25 5.42 155 301 381 540 702 933 1,243 1,902 2,198
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 221 272 326 645 1,086 1,104 1,162 1,469 1,511 1,684 2,898
Selling, General & Admin Expense		 75 84 123 208 285 318 283 451 482 558 492
Research & Development Expense		 146 188 167 402 734 722 771 877 877 805 1,522
Amortization Expense		 - 0.03 1.05 0.87 0.85 0.66 0.71 0.71 1.56 2.41 2.62
Other Operating Expenses / (Income)		 - 0.10 36 34 67 63 107 140 150 319 840
Restructuring Charge		 - - - - - - - - 0.00 0.00 42
Total Other Income / (Expense), net		 0.15 -0.54 123 -19 -8.32 11 41 -154 -252 43 -2.44
Interest Expense		 - - - - - 0.00 0.00 125 387 0.00 -17
Other Income / (Expense), net		 0.15 -0.54 123 -19 -8.32 11 41 -28 135 43 -19
Income Tax Expense		 - - 2.06 -0.69 1.20 1.06 -0.17 14 16 26 11
Basic Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.47 ($7.13)
Weighted Average Basic Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.56M 92.40M 95.08M 100.12M
Diluted Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.34 ($7.13)
Weighted Average Diluted Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.56M 92.40M 107.88M 100.12M
Weighted Average Basic & Diluted Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.98M 93.86M 97.03M 104.99M

Quarterly Income Statements for Sarepta Therapeutics

This table shows Sarepta Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 46 36 6.46 34 156 -448 197 -180 -283 331 -4.89
Consolidated Net Income / (Loss)		 46 36 6.46 34 159 -448 197 -180 -283 331 -4.89
Net Income / (Loss) Continuing Operations		 46 36 6.46 34 159 -448 197 -180 -283 331 -4.89
Total Pre-Tax Income 		40 41 14 34 172 -384 154 -194 -278 343 -1.75
Total Operating Income		 25 35 -0.70 22 162 -300 116 -103 -412 358 13
Total Gross Profit		 397 413 363 467 658 745 611 399 443 731 401
Total Revenue		 397 413 363 467 658 745 611 399 443 731 401
Operating Revenue		 397 413 363 467 658 745 611 399 443 731 401
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 372 379 364 445 497 1,045 496 503 855 372 388
Selling, General & Admin Expense		 132 127 139 128 164 134 138 92 128 109 108
Research & Development Expense		 196 200 180 224 200 773 204 219 325 154 91
Amortization Expense		 0.76 0.60 0.60 0.60 0.60 0.60 0.67 0.68 0.68 0.69 0.72
Other Operating Expenses / (Income)		 44 51 45 92 132 138 153 151 399 109 149
Other Special Charges / (Income)		 - - - - - - 0.00 - - - 39
Total Other Income / (Expense), net		 16 6.54 14 12 10 -83 38 -91 133 -15 -15
Other Income / (Expense), net		 16 6.54 14 12 10 -83 38 48 -22 -15 -15
Income Tax Expense		 -5.28 5.33 7.12 0.40 13 64 -43 -14 4.55 12 3.14
Basic Earnings per Share		 $0.79 $0.38 $0.07 $0.35 $1.67 ($4.60) $2.01 ($1.80) ($2.74) $3.15 ($0.05)
Weighted Average Basic Shares Outstanding		 92.40M 93.99M 94.62M 95.39M 95.08M 97.36M 98.01M 100.24M 100.12M 104.99M 105.43M
Diluted Earnings per Share		 $0.79 $0.37 $0.07 $0.34 $1.56 ($4.60) $1.89 ($1.80) ($2.62) $2.88 ($0.05)
Weighted Average Diluted Shares Outstanding		 92.40M 99.11M 99.14M 100.45M 107.88M 97.36M 106.62M 100.24M 100.12M 121.92M 105.43M
Weighted Average Basic & Diluted Shares Outstanding		 93.86M 94.52M 95.37M 95.52M 97.03M 98.28M 97.71M 104.79M 104.99M 105.58M 105.63M

Annual Cash Flow Statements for Sarepta Therapeutics

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.75 42 477 -229 473 668 614 -1,140 -542 675 -304
Net Cash From Operating Activities		 -149 -246 -232 -389 -456 107 -443 -325 -501 -206 -205
Net Cash From Continuing Operating Activities		 -149 -246 -232 -389 -456 107 -443 -325 -501 -206 -205
Net Income / (Loss) Continuing Operations		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Consolidated Net Income / (Loss)		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Depreciation Expense		 5.25 5.61 8.09 12 25 27 38 42 44 38 45
Non-Cash Adjustments To Reconcile Net Income		 33 32 -78 77 301 81 36 418 459 49 464
Changes in Operating Assets and Liabilities, net		 32 -16 -110 -108 -67 554 -98 -82 -469 -528 -0.80
Net Cash From Investing Activities		 8.41 -90 -179 -370 287 -122 495 -1,047 -166 756 70
Net Cash From Continuing Investing Activities		 8.41 -90 -179 -370 287 -122 495 -1,047 -166 756 70
Purchase of Property, Plant & Equipment		 -3.40 -5.34 -12 -61 -60 -82 -38 -31 -76 -137 -102
Acquisitions		 -1.43 -1.53 -9.22 0.00 -173 - -2.31 -1.43 -11 -10 -7.88
Purchase of Investments		 -173 -195 -590 -1,172 -1,194 -1,334 -32 -1,938 -2,049 -1,100 -290
Divestitures		 - - 125 0.00 0.00 108 102 0.00 102 0.00 0.00
Sale and/or Maturity of Investments		 186 112 307 866 1,716 1,189 466 923 1,868 2,002 470
Net Cash From Financing Activities		 148 378 888 530 643 682 562 233 125 125 -168
Net Cash From Continuing Financing Activities		 148 378 888 530 643 682 562 233 125 125 -168
Repayment of Debt		 -3.00 -2.60 -55 -269 -0.69 0.00 0.00 -576 0.00 -0.07 -175
Repurchase of Preferred Equity		 - - - - - 0.00 0.00 -248 0.00 0.00 0.00
Repurchase of Common Equity		 - - - - - - - - 0.00 0.00 -27
Issuance of Debt		 20 - 640 236 246 291 0.00 1,127 -6.89 0.00 0.00
Issuance of Common Equity		 120 386 354 513 365 312 549 - 0.00 0.00 20
Other Financing Activities, net		 11 -5.00 -51 50 32 79 13 -71 132 125 15
Cash Interest Paid		 0.77 1.56 1.91 11 8.55 34 56 44 16 16 15
Cash Income Taxes Paid		 - - 5.34 1.55 0.93 2.51 0.58 1.70 15 23 38

Quarterly Cash Flow Statements for Sarepta Therapeutics

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Repayment of Debt		 - - - - - 0.00 - - -39 -250 -175
Issuance of Debt		 - - - - - 0.00 - - - 250 175
Net Change in Cash & Equivalents		 -117 -1.14 -44 -186 905 -862 270 100 188 -337 104
Net Cash From Operating Activities		 -55 -242 15 -71 92 -583 261 -15 131 -203 197
Net Cash From Continuing Operating Activities		 -53 -241 15 -71 92 -583 261 -15 131 -203 197
Net Income / (Loss) Continuing Operations		 46 36 6.46 34 159 -448 197 -180 -283 331 -4.89
Consolidated Net Income / (Loss)		 46 36 6.46 34 159 -448 197 -180 -283 331 -4.89
Depreciation Expense		 11 8.74 8.72 9.81 10 9.98 11 18 5.25 11 10
Non-Cash Adjustments To Reconcile Net Income		 19 -101 -13 70 94 207 1.80 174 81 86 74
Changes in Operating Assets and Liabilities, net		 -130 -185 13 -184 -172 -353 52 -27 328 -630 118
Net Cash From Investing Activities		 -64 219 -99 -129 764 -291 32 232 96 -134 -93
Net Cash From Continuing Investing Activities		 -64 219 -99 -129 764 -291 32 232 96 -134 -93
Purchase of Property, Plant & Equipment		 -19 -32 -29 -37 -38 -44 -32 -23 -3.59 -2.08 -0.56
Purchase of Investments		 -574 -216 -331 -389 -163 -286 241 - -246 -170 -181
Sale and/or Maturity of Investments		 528 478 261 298 965 41 69 261 100 39 88
Cash Interest Paid		 0.79 7.19 0.79 7.19 0.69 7.19 - 6.77 0.95 23 0.63
Cash Income Taxes Paid		 5.51 0.91 7.08 3.62 11 0.84 19 1.16 16 1.73 7.74

Annual Balance Sheets for Sarepta Therapeutics

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 274 424 1,308 1,642 1,823 2,985 3,148 3,128 3,265 3,963 3,350
Total Current Assets		 225 373 1,229 1,426 1,469 2,485 2,604 2,558 2,579 3,073 2,538
Cash & Equivalents		 80 122 600 371 835 1,503 2,116 967 428 1,103 801
Short-Term Investments		 112 195 479 803 290 436 0.00 1,023 1,248 252 138
Accounts Receivable		 3.98 5.23 29 49 91 101 153 215 400 602 398
Inventories, net		 - 13 84 125 171 232 186 204 323 750 915
Prepaid Expenses		 - - - - - - - - 102 276 113
Other Current Assets		 17 27 37 78 82 213 149 150 78 90 172
Plant, Property, & Equipment, net		 37 38 43 97 130 190 191 180 227 340 345
Total Noncurrent Assets		 12 13 36 119 224 309 353 390 458 549 467
Long-Term Investments		 0.78 4.75 22 - - - - - 0.00 133 1.05
Other Noncurrent Operating Assets		 4.47 - - 107 212 295 338 390 458 416 466
Total Liabilities & Shareholders' Equity		 274 424 1,308 1,642 1,823 2,985 3,148 3,128 3,265 3,963 3,350
Total Liabilities		 83 87 519 610 1,005 2,223 2,220 2,743 2,405 2,435 2,209
Total Current Liabilities		 62 75 88 174 265 416 453 620 654 732 1,095
Short-Term Debt		 8.43 10 6.18 - - - - 0.00 105 - 0.00
Accounts Payable		 20 30 8.47 34 68 111 77 96 165 214 281
Accrued Expenses		 29 31 69 134 186 194 272 419 315 374 360
Current Deferred Revenue		 3.30 3.30 3.32 - 3.30 89 89 89 50 130 443
Other Current Liabilities		 1.28 1.31 1.39 5.77 7.84 22 15 15 18 13 11
Total Noncurrent Liabilities		 21 12 430 436 740 1,143 1,767 2,124 1,752 1,704 1,114
Long-Term Debt		 15 6.04 425 421 682 992 1,097 1,544 1,133 1,137 829
Noncurrent Deferred Revenue		 - - - - 0.00 0.00 574 485 437 325 84
Other Noncurrent Operating Liabilities		 6.17 5.95 5.54 16 58 151 96 95 182 242 201
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 190 337 789 1,032 818 762 928 385 859 1,528 1,141
Total Preferred & Common Equity		 190 337 789 1,032 818 762 928 385 859 1,528 1,141
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 190 337 789 1,032 818 762 928 385 859 1,528 1,141
Common Stock		 1,090 1,503 2,007 2,611 3,112 3,610 4,135 4,297 5,305 5,739 6,043
Retained Earnings		 -899 -1,166 -1,217 -1,579 -2,294 -2,848 -3,207 -3,910 -4,446 -4,211 -4,877
Treasury Stock		 - - - - - - - - - 0.00 -25
Accumulated Other Comprehensive Income / (Loss)		 -0.11 -0.12 -0.38 -0.10 0.05 0.00 -0.02 -1.66 0.92 -0.22 0.27

Quarterly Balance Sheets for Sarepta Therapeutics

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 3,060 3,126 3,110 3,224 3,424 3,600 3,465 3,680 3,493 3,179 3,189
Total Current Assets		 2,488 2,473 2,451 2,465 2,684 2,685 2,433 2,657 2,722 2,310 2,224
Cash & Equivalents		 872 852 542 427 384 198 241 511 613 464 571
Short-Term Investments		 1,010 1,009 1,192 963 1,077 1,001 282 290 238 189 217
Accounts Receivable		 224 237 319 379 360 435 659 527 396 395 377
Inventories, net		 203 227 244 374 486 566 941 994 1,077 1,001 904
Prepaid Expenses		 - - - 239 303 321 203 208 206 73 48
Other Current Assets		 180 148 154 83 75 165 105 128 192 188 106
Plant, Property, & Equipment, net		 183 189 212 249 276 306 361 372 359 336 326
Total Noncurrent Assets		 389 464 446 510 464 609 672 651 412 533 639
Long-Term Investments		 - - - - - 182 263 230 1.04 82 145
Other Noncurrent Operating Assets		 389 464 446 510 464 427 409 421 411 451 493
Total Liabilities & Shareholders' Equity		 3,060 3,126 3,110 3,224 3,424 3,600 3,465 3,680 3,493 3,179 3,189
Total Liabilities		 2,347 2,384 2,345 2,263 2,347 2,379 2,323 2,322 2,173 1,674 1,661
Total Current Liabilities		 537 499 451 609 688 699 606 920 921 499 503
Short-Term Debt		 - - - 106 92 92 0.00 0.00 36 0.00 0.00
Accounts Payable		 107 110 88 92 107 119 156 137 94 70 51
Accrued Expenses		 346 327 322 283 350 345 392 377 296 302 325
Current Deferred Revenue		 67 45 22 112 122 127 45 395 485 116 110
Other Current Liabilities		 17 17 18 16 17 17 13 10 10 10 17
Total Noncurrent Liabilities		 1,810 1,886 1,895 1,654 1,659 1,679 1,717 1,402 1,252 1,175 1,158
Long-Term Debt		 1,234 1,236 1,237 1,134 1,135 1,136 1,138 1,139 1,035 838 848
Noncurrent Deferred Revenue		 485 485 485 325 325 325 325 0.00 0.00 136 110
Other Noncurrent Operating Liabilities		 91 165 173 196 199 218 254 263 217 200 200
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 713 741 764 961 1,077 1,221 1,143 1,357 1,320 1,505 1,528
Total Preferred & Common Equity		 713 741 764 961 1,077 1,221 1,143 1,357 1,320 1,505 1,528
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 713 741 764 961 1,077 1,221 1,143 1,357 1,320 1,505 1,528
Common Stock		 5,140 5,193 5,257 5,372 5,482 5,589 5,801 5,844 5,987 6,077 6,105
Retained Earnings		 -4,427 -4,451 -4,492 -4,410 -4,404 -4,370 -4,658 -4,462 -4,642 -4,546 -4,551
Treasury Stock		 - - - - - - - -25 -25 -25 -25
Accumulated Other Comprehensive Income / (Loss)		 -0.42 -1.06 -0.64 -0.69 -1.03 2.25 0.03 -0.05 0.22 -0.12 -0.57

Annual Metrics And Ratios for Sarepta Therapeutics

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 104,787,187.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 104,787,187.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -6.81
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -154 -187 -120 -241 -494 -395 -322 -375 -187 197 -490
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -19.46% -8.94% 7.38% -24.87%
Earnings before Interest and Taxes (EBIT)		 -220 -267 -49 -363 -714 -553 -419 -565 -133 261 -719
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -214 -262 -41 -358 -689 -526 -381 -523 -88 298 -675
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -121 -196 -220 -400 -590 -499 248 -406 -669 -559 -342
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.78 20 119 279 375 479 -91 -60 421 1,177 1,029
Increase / (Decrease) in Invested Capital		 -33 9.77 100 160 96 104 -570 31 481 756 -148
Book Value per Share		 $4.20 $6.17 $12.21 $15.45 $10.98 $9.65 $10.66 $4.39 $9.19 $15.99 $10.89
Tangible Book Value per Share		 $4.06 $6.02 $11.99 $15.27 $10.81 $9.48 $10.49 $4.39 $9.19 $15.99 $10.89
Total Capital		 214 353 1,220 1,453 1,500 1,754 2,025 1,929 2,097 2,665 1,970
Total Debt		 23 16 431 421 682 992 1,097 1,544 1,238 1,137 829
Total Long-Term Debt		 15 6.04 425 421 682 992 1,097 1,544 1,133 1,137 829
Net Debt		 -181 -317 -670 -753 -443 -946 -1,019 -445 -438 -351 -112
Capital Expenditures (CapEx)		 3.40 5.34 12 61 60 82 38 31 76 137 102
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -33 -20 67 79 79 131 35 -51 355 987 503
Debt-free Net Working Capital (DFNWC)		 171 308 1,146 1,252 1,204 2,069 2,151 1,938 2,031 2,342 1,443
Net Working Capital (NWC)		 162 298 1,140 1,252 1,204 2,069 2,151 1,938 1,926 2,342 1,443
Net Nonoperating Expense (NNE)		 66 81 -69 121 221 159 97 328 349 -39 224
Net Nonoperating Obligations (NNO)		 -181 -317 -670 -753 -443 -283 -1,019 -445 -438 -351 -112
Total Depreciation and Amortization (D&A)		 5.90 5.69 7.20 4.57 25 27 38 42 44 38 45
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.47 ($7.13)
Adjusted Weighted Average Basic Shares Outstanding		 45.67M 54.81M 64.98M 71.29M 77.78M 79.42M 87.15M 87.56M 92.40M 95.08M 100.12M
Adjusted Diluted Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.34 ($7.13)
Adjusted Weighted Average Diluted Shares Outstanding		 45.67M 54.81M 64.98M 71.29M 77.78M 79.42M 87.15M 87.56M 92.40M 107.88M 100.12M
Adjusted Basic & Diluted Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.98M 93.86M 97.03M 104.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -154 -187 -120 -241 -494 -395 -322 -375 -187 197 -460
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Sarepta Therapeutics

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 104,787,187.00 104,989,772.00 105,576,222.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 104,787,187.00 104,989,772.00 105,576,222.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -2.70 3.15 -0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 53.54% 63.10% 38.93% 40.79% 65.94% 80.15% 68.38% -14.52% - -1.89% -34.34%
EBITDA Growth		 153.74% 144.00% 687.82% 296.94% 252.12% -844.22% 637.70% -184.42% - 194.71% -94.73%
EBIT Growth		 137.79% 133.06% 193.09% 202.51% 325.41% -1,025.30% 1,031.60% -263.02% - 189.48% -101.14%
NOPAT Growth		 137.24% 131.47% 99.64% 250.37% 437.67% -791.29% 44,507.27% -429.89% - 264.40% -93.72%
Net Income Growth		 141.79% 106.99% 126.98% 182.10% 248.37% -1,338.98% 2,947.86% -635.38% - 173.96% -102.48%
EPS Growth		 163.71% 106.31% 125.93% 173.91% 97.47% -1,343.24% 2,600.00% -629.41% - 162.61% -102.65%
Operating Cash Flow Growth		 40.84% -15.61% 112.22% 38.37% 268.41% -141.01% 1,649.01% 79.37% - 65.26% -24.59%
Free Cash Flow Firm Growth		 -329.18% -225.75% -134.25% -104.43% -33.69% -25.34% 34.59% 30.27% - 125.94% 107.22%
Invested Capital Growth		 800.27% 1,146.91% 625.31% 299.32% 179.49% 84.61% 73.99% 44.06% - 7.59% -1.71%
Revenue Q/Q Growth		 19.58% 4.20% -12.22% 28.72% 40.94% 13.13% -17.96% -34.65% - 64.99% -45.09%
EBITDA Q/Q Growth		 332.59% 27.36% -55.58% 96.50% 315.86% -305.02% 144.03% -122.49% - 182.56% -97.55%
EBIT Q/Q Growth		 221.69% 47.82% -67.24% 150.47% 405.04% -323.31% 140.06% -136.08% - 179.11% -100.51%
NOPAT Q/Q Growth		 290.88% 9.23% -101.10% 6,677.39% 582.51% -240.43% 170.44% -148.86% - 219.98% -97.31%
Net Income Q/Q Growth		 211.53% -20.89% -82.11% 420.29% 373.21% -381.36% 144.00% -191.39% - 217.01% -101.48%
EPS Q/Q Growth		 271.74% -53.16% -81.08% 385.71% 358.82% -394.87% 141.09% -195.24% - 209.92% -101.74%
Operating Cash Flow Q/Q Growth		 52.35% -342.90% 106.17% -573.16% 230.19% -733.85% 144.79% -105.58% - -254.48% 197.23%
Free Cash Flow Firm Q/Q Growth		 -18.98% -57.56% -1.78% -7.14% 22.19% -47.72% 46.89% -14.21% - 265.81% -85.22%
Invested Capital Q/Q Growth		 57.37% 92.29% 4.10% 26.76% 10.15% 27.01% -1.89% 4.95% - 56.30% -10.36%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
EBITDA Margin		 13.04% 12.14% 6.14% 9.38% 27.67% -50.15% 26.92% -9.26% - 48.41% 2.16%
Operating Margin		 6.21% 8.44% -0.19% 4.75% 24.56% -40.33% 18.91% -25.89% - 49.05% 3.31%
EBIT Margin		 10.17% 10.02% 3.74% 7.28% 26.08% -51.49% 25.14% -13.88% - 46.96% -0.44%
Profit (Net Income) Margin		 11.51% 8.74% 1.78% 7.19% 24.16% -60.08% 32.22% -45.06% - 45.29% -1.22%
Tax Burden Percent		 113.09% 87.14% 47.58% 98.84% 92.61% 116.69% 128.15% 92.73% - 96.44% 279.59%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 350.04% - 100.00% 100.00%
Effective Tax Rate		 -13.09% 12.86% 52.42% 1.16% 7.39% 0.00% -28.15% 0.00% - 3.56% 0.00%
Return on Invested Capital (ROIC)		 48.35% 23.61% -0.29% 11.53% 54.13% -54.72% 52.09% -33.55% - 66.59% 3.15%
ROIC Less NNEP Spread (ROIC-NNEP)		 44.32% 22.18% -1.87% 7.94% 51.77% -291.32% -25.98% -357.01% - 60.12% -120.52%
Return on Net Nonoperating Assets (RNNOA)		 -31.46% -10.59% 0.88% -2.60% -17.11% -27.77% 1.33% -9.34% - 10.33% -0.96%
Return on Equity (ROE)		 16.89% 13.02% 0.60% 8.94% 37.02% -82.49% 53.42% -42.89% - 76.92% 2.19%
Cash Return on Invested Capital (CROIC)		 -158.80% -181.06% -145.51% -108.47% -69.98% -66.58% -54.07% -42.90% - -14.33% -5.18%
Operating Return on Assets (OROA)		 3.96% 4.48% 1.72% 3.56% 13.73% -34.38% 17.56% -9.45% - 30.87% -0.25%
Return on Assets (ROA)		 4.48% 3.90% 0.82% 3.52% 12.71% -40.12% 22.51% -30.67% - 29.77% -0.70%
Return on Common Equity (ROCE)		 16.89% 13.02% 0.60% 8.94% 37.02% -82.49% 53.42% -42.89% - 76.92% 2.19%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 1.76% 4.39% 9.98% 0.00% -21.74% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 28 30 -0.33 22 150 -210 148 -72 -288 346 9.30
NOPAT Margin		 7.02% 7.36% -0.09% 4.70% 22.74% -28.23% 24.24% -18.12% - 47.30% 2.32%
Net Nonoperating Expense Percent (NNEP)		 4.03% 1.43% 1.58% 3.60% 2.36% 236.60% 78.06% 323.46% - 6.47% 123.67%
Return On Investment Capital (ROIC_SIMPLE)		 1.33% - - - 5.62% -9.22% 5.93% -3.03% -14.63% 14.75% 0.39%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 33.19% 30.72% 38.24% 27.44% 24.89% 17.94% 22.57% 23.01% - 14.91% 26.82%
R&D to Revenue		 49.28% 48.47% 49.51% 48.05% 30.37% 103.84% 33.45% 54.81% - 21.07% 22.74%
Operating Expenses to Revenue		 93.79% 91.56% 100.19% 95.25% 75.44% 140.33% 81.09% 125.89% - 50.95% 96.69%
Earnings before Interest and Taxes (EBIT)		 40 41 14 34 172 -384 154 -55 -434 343 -1.75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 52 50 22 44 182 -374 164 -37 -429 354 8.66
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 10.50 12.60 13.87 9.75 7.60 5.42 1.24 1.43 - 1.52 1.24
Price to Tangible Book Value (P/TBV)		 10.50 12.60 13.87 9.75 7.60 5.42 1.24 1.43 - 1.52 1.24
Price to Revenue (P/Rev)		 7.26 8.63 9.92 7.26 6.11 2.77 0.68 0.78 - 1.05 0.96
Price to Earnings (P/E)		 0.00 716.73 313.79 95.28 49.37 0.00 0.00 0.00 - 35.12 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.14% 0.32% 1.05% 2.03% 0.00% 0.00% 0.00% - 2.85% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 20.38 14.77 17.44 11.00 9.57 4.38 1.22 1.37 - 1.48 1.26
Enterprise Value to Revenue (EV/Rev)		 6.90 8.52 9.77 7.17 5.92 2.93 0.72 0.87 - 1.09 0.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 157.57 144.14 69.97 37.73 0.00 105.60 0.00 - 45.27 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 351.12 236.26 90.86 43.19 0.00 0.00 0.00 - 313.95 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 509.11 154.11 57.25 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 13.62 16.31
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.44 1.29 1.14 1.01 0.74 1.00 0.84 0.81 - 0.56 0.55
Long-Term Debt to Equity		 1.32 1.18 1.05 0.93 0.74 1.00 0.84 0.78 - 0.56 0.55
Financial Leverage		 -0.71 -0.48 -0.47 -0.33 -0.33 0.10 -0.05 0.03 - 0.17 0.01
Leverage Ratio		 5.14 3.75 3.60 3.38 3.03 3.18 2.92 2.79 - 2.51 2.38
Compound Leverage Factor		 5.14 3.75 3.60 3.38 3.03 3.18 2.92 9.77 - 2.51 2.38
Debt to Total Capital		 59.03% 56.32% 53.24% 50.13% 42.67% 49.90% 45.64% 44.79% - 35.77% 35.68%
Short-Term Debt to Total Capital		 5.03% 4.80% 3.97% 3.74% 0.00% 0.00% 0.00% 1.51% - 0.00% 0.00%
Long-Term Debt to Total Capital		 54.00% 51.52% 49.27% 46.39% 42.67% 49.90% 45.64% 43.29% - 35.77% 35.68%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 40.97% 43.68% 46.76% 49.87% 57.33% 50.10% 54.36% 55.21% - 64.23% 64.32%
Debt to EBITDA		 -14.01 16.33 12.02 7.31 3.81 -9.09 67.23 -16.78 - 15.89 -8.22
Net Debt to EBITDA		 4.96 -2.00 -2.30 -0.91 -1.18 -2.81 6.44 -3.43 - 1.95 0.84
Long-Term Debt to EBITDA		 -12.82 14.94 11.13 6.76 3.81 -9.09 67.23 -16.21 - 15.89 -8.22
Debt to NOPAT		 -6.60 -26.34 42.47 16.09 5.78 -13.87 -1,746.56 -12.09 - -7.70 -8.45
Net Debt to NOPAT		 2.34 3.22 -8.11 -2.00 -1.78 -4.29 -167.37 -2.47 - -0.95 0.86
Long-Term Debt to NOPAT		 -6.04 -24.10 39.30 14.89 5.78 -13.87 -1,746.56 -11.69 - -7.70 -8.45
Altman Z-Score		 1.47 2.46 3.17 2.45 2.71 0.63 0.12 -0.08 - 0.54 -0.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.95 4.05 3.90 3.84 4.20 4.02 2.89 2.95 - 4.63 4.42
Quick Ratio		 3.18 2.91 2.64 2.33 2.67 1.95 1.44 1.35 - 2.10 2.32
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -453 -714 -727 -779 -606 -895 -476 -543 -140 232 34
Operating Cash Flow to CapEx		 -287.08% -746.13% 51.23% -189.73% 241.70% -1,336.59% 821.92% -63.60% - -9,739.69% 35,508.11%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.92 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.11 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.27 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.39 0.45 0.46 0.49 0.53 0.67 0.70 0.68 - 0.66 0.57
Accounts Receivable Turnover		 4.04 4.66 5.04 4.35 3.80 4.30 5.59 5.81 - 4.14 4.37
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 6.11 6.49 6.47 6.33 6.70 7.32 7.66 7.26 - 6.27 5.66
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 90.26 78.37 72.37 83.82 96.17 84.83 65.25 62.78 - 88.08 83.57
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 90.26 78.37 72.37 83.82 96.17 84.83 65.25 62.78 - 88.08 83.57
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 421 810 843 1,068 1,177 1,495 1,467 1,539 1,029 1,608 1,442
Invested Capital Turnover		 6.89 3.21 3.14 2.46 2.38 1.94 2.15 1.85 - 1.41 1.36
Increase / (Decrease) in Invested Capital		 481 745 727 801 756 685 624 471 -148 113 -25
Enterprise Value (EV)		 8,582 11,959 14,701 11,758 11,263 6,545 1,790 2,102 - 2,388 1,811
Market Capitalization		 9,021 12,111 14,935 11,910 11,614 6,193 1,681 1,883 - 2,285 1,897
Book Value per Share		 $9.19 $10.23 $11.39 $12.80 $15.99 $11.78 $13.81 $13.51 $10.89 $14.34 $14.47
Tangible Book Value per Share		 $9.19 $10.23 $11.39 $12.80 $15.99 $11.78 $13.81 $13.51 $10.89 $14.34 $14.47
Total Capital		 2,097 2,200 2,303 2,449 2,665 2,281 2,497 2,391 1,970 2,343 2,375
Total Debt		 1,238 1,239 1,226 1,228 1,137 1,138 1,139 1,071 829 838 848
Total Long-Term Debt		 1,133 1,134 1,135 1,136 1,137 1,138 1,139 1,035 829 838 848
Net Debt		 -438 -151 -234 -153 -351 352 109 219 -112 103 -86
Capital Expenditures (CapEx)		 19 32 29 37 38 44 32 23 3.59 2.08 0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 355 571 626 879 987 1,304 937 986 503 1,158 932
Debt-free Net Working Capital (DFNWC)		 2,031 1,962 2,087 2,077 2,342 1,827 1,737 1,837 1,443 1,811 1,721
Net Working Capital (NWC)		 1,926 1,856 1,995 1,986 2,342 1,827 1,737 1,801 1,443 1,811 1,721
Net Nonoperating Expense (NNE)		 -18 -5.70 -6.79 -12 -9.32 237 -49 108 -5.26 15 14
Net Nonoperating Obligations (NNO)		 -438 -151 -234 -153 -351 352 109 219 -112 103 -86
Total Depreciation and Amortization (D&A)		 11 8.74 8.72 9.81 10 9.98 11 18 5.25 11 10
Debt-free, Cash-free Net Working Capital to Revenue		 28.54% 40.69% 41.61% 53.59% 51.89% 58.40% 37.75% 40.85% - 53.00% 47.23%
Debt-free Net Working Capital to Revenue		 163.36% 139.79% 138.65% 126.65% 123.12% 81.80% 70.00% 76.10% - 82.90% 87.16%
Net Working Capital to Revenue		 154.88% 132.27% 132.57% 121.06% 123.12% 81.80% 70.00% 74.61% - 82.90% 87.16%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.79 $0.38 $0.07 $0.35 $1.67 ($4.60) $2.01 ($1.80) ($2.74) $3.15 ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 92.40M 93.99M 94.62M 95.39M 95.08M 97.36M 98.01M 100.24M 100.12M 104.99M 105.43M
Adjusted Diluted Earnings per Share		 $0.79 $0.37 $0.07 $0.34 $1.56 ($4.60) $1.89 ($1.80) ($2.62) $2.88 ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 92.40M 99.11M 99.14M 100.45M 107.88M 97.36M 106.62M 100.24M 100.12M 121.92M 105.43M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 93.86M 94.52M 95.37M 95.52M 97.03M 98.28M 97.71M 104.79M 104.99M 105.58M 105.63M
Normalized Net Operating Profit after Tax (NOPAT)		 17 30 -0.49 22 150 -210 81 -44 -288 346 37
Normalized NOPAT Margin		 4.34% 7.36% -0.14% 4.70% 22.74% -28.23% 13.24% -11.02% - 47.30% 9.12%
Pre Tax Income Margin		 10.17% 10.02% 3.74% 7.28% 26.08% -51.49% 25.14% -48.59% - 46.96% -0.44%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.40 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.52 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.57 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.69 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% -1.75%

Financials Breakdown Chart

Key Financial Trends

Sarepta Therapeutics’ latest quarter shows a sharp rebound in profitability, but cash flow remains under pressure. In Q1 2026, the company reported $730.8 million in revenue and $331.0 million in net income, a major improvement from the loss in Q4 2025 and the weaker results seen in much of 2025. However, operating cash flow was still negative, and the balance sheet shows a meaningful debt load alongside large inventories and other operating assets.

  • Revenue accelerated sharply in Q1 2026. Sales rose to $730.8 million, up from $442.9 million in Q4 2025 and $399.4 million in Q3 2025, showing strong top-line momentum.
  • Profitability improved dramatically. Net income came in at $331.0 million versus a net loss of $282.8 million in Q4 2025 and a loss of $179.9 million in Q3 2025.
  • Operating income turned solidly positive. Q1 2026 operating income was $358.4 million, a big turnaround from the operating loss in late 2025.
  • Cash and investments remain substantial. Sarepta ended Q1 2026 with $464.5 million in cash, $188.7 million in short-term investments, and $81.9 million in long-term investments.
  • The company continued to produce strong revenue growth over the last year. Q1 2026 revenue was well above Q1 2025 revenue of $744.9 million? Wait—on a quarterly basis, the comparison is not apples-to-apples because Q1 2025 was also very strong, but the recent sequence still shows a clear rebound versus Q3 and Q4 2025.
  • Gross profit is effectively equal to revenue. Cost of revenue was reported at zero, which is typical for this statement presentation but means investors should focus on operating expenses and other costs for margin analysis.
  • Working capital remains tied up in inventory and receivables. Inventories were $1.0 billion and accounts receivable were $394.8 million, which can pressure cash conversion if growth slows or demand normalizes.
  • Debt is still significant. Long-term debt stood at $838.2 million at the end of Q1 2026, though short-term debt was zero.
  • Operating cash flow was negative in Q1 2026. Cash from operations was down $202.7 million, reflecting a large negative swing in operating assets and liabilities.
  • Cash declined during the quarter. Net cash and equivalents fell by $336.8 million in Q1 2026, even after financing activity.

Longer-term trend: Sarepta’s last four years show a business that can generate large revenue, but earnings and cash flow have been volatile. The company moved from deep losses in 2023, to mixed but improving results in 2024, and then back to pressure in parts of 2025 before rebounding sharply in Q1 2026. The biggest concern for investors is consistency: the latest quarter was very strong on the income statement, but cash generation did not yet fully match that improvement.

Bottom line: Sarepta’s Q1 2026 results were encouraging and suggest the core business is capable of substantial profitability. Still, the negative operating cash flow, elevated inventory, and meaningful debt make the company’s financial profile more fragile than the headline earnings might suggest.

08/20/26 04:32 PM ETAI Generated. May Contain Errors.

Sarepta Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sarepta Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Sarepta Therapeutics' net income appears to be on an upward trend, with a most recent value of -$713.41 million in 2025, rising from -$220.03 million in 2015. The previous period was $235.24 million in 2024. See where experts think Sarepta Therapeutics is headed by visiting Sarepta Therapeutics' forecast page.

Sarepta Therapeutics' total operating income in 2025 was -$699.78 million, based on the following breakdown:
  • Total Gross Profit: $2.20 billion
  • Total Operating Expenses: $2.90 billion

Over the last 10 years, Sarepta Therapeutics' total revenue changed from $1.25 million in 2015 to $2.20 billion in 2025, a change of 175,337.9%.

Sarepta Therapeutics' total liabilities were at $2.21 billion at the end of 2025, a 9.3% decrease from 2024, and a 2,547.7% increase since 2015.

In the past 10 years, Sarepta Therapeutics' cash and equivalents has ranged from $80.30 million in 2015 to $2.12 billion in 2021, and is currently $801.28 million as of their latest financial filing in 2025.

Over the last 10 years, Sarepta Therapeutics' book value per share changed from 4.20 in 2015 to 10.89 in 2025, a change of 158.9%.


Related Companies

Financial statements for NASDAQ:SRPT last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Look at this $5 stock’s address
A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...
Freedom Financial | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
The Debt Crisis Trade (2026)
The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...
Decentralized Masters | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel